Spinowitz Bruce S
New York Hospital, Queens, Clinical Professor of Medicine, Cornell University Medical Center, New York, NY, USA.
Haematologica. 2008 May;93(5):761-4. doi: 10.3324/haematol.10985. Epub 2008 Mar 26.
In a one-year, multicenter, open-label, uncontrolled trial, epoetin delta was given subcutaneously, 1-3-times weekly to peritoneal dialysis patients who had previously received an epoetin. Dose was adjusted to maintain hemoglobin at 10.0-12.0 g/dL. The primary endpoint was mean hemoglobin over weeks 12-24. Safety was assessed. Mean+/-SD baseline hemoglobin was 11.2+/-0.9 g/dL. Hemoglobin over weeks 12-24 was 11.6+/-1.1 g/dL. Adverse events were those expected in this patient population. No life-threatening adverse events occurred. Subcutaneous epoetin delta was effective and well tolerated for the treatment of anemia in peritoneal dialysis patients.
在一项为期一年的多中心、开放标签、非对照试验中，对之前接受过促红细胞生成素治疗的腹膜透析患者皮下注射δ-促红细胞生成素，每周1至3次。调整剂量以使血红蛋白维持在10.0 - 12.0 g/dL。主要终点是第12至24周的平均血红蛋白水平。对安全性进行了评估。平均±标准差基线血红蛋白为11.2±0.9 g/dL。第12至24周的血红蛋白为11.6±1.1 g/dL。不良事件为该患者群体中预期出现的事件。未发生危及生命的不良事件。皮下注射δ-促红细胞生成素治疗腹膜透析患者贫血有效且耐受性良好。
